Significant progress on respiratory programmes
at £36.5m (2012/13: £30.5m)
Breakthrough for generic respiratory products
compared to a loss in previous year (2012/13: loss of £3.4m)
1 Earnings before investment income, finance
gains, tax, depreciation, amortisation, share-based compensation and adjusted for non-recurring expenditure.
Strategic growth and pipeline augmentation
Loss before tax
to £4.8m (2012/13: £10.4m)
Balance sheet strength maintained with cash and
cash equivalents of
(£70.1m at 31 March 2013)
Our therapeutic focus is to develop products for airways-related diseases. These include major diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and is a market estimated to be worth in excess of US$46bn worldwide1. This segment of the market covers a wide range of other indications including cough, severe inflammation, cystic fibrosis, allergic rhinitis, and fibrotic diseases of the lung.
1 Pharmaview Commercial Landscape Series Respiratory Decision Resources 2013.Download Our business at a glance
Global respiratory market estimated worth:
How we work
We develop products in-house and in collaboration with pharmaceutical partners, leveraging investment in our intellectual property and, where possible, mitigating the risk of our business.Download Our business at a glance
Vectura has disclosed development collaborations, joint ventures and licence agreements with several pharmaceutical and biotechnology companies, including:
At Vectura we bring our values to reality through the way we operate.
We have a strong foundation of core company values. Everything we do stems from our five key values and these are reflected in the way we operate our business, both internally and externally, which ensures we express clearly our vision and values and the behaviours necessary to realise our strategic ambitions.
Vectura is transitioning into a leading specialty pharmaceutical company that focuses on developing innovative treatments for
Bruno Angelici ChairmanDownload full statement
Vectura has evolved into the product-focused company it is today. The recent acquisition provides important pipeline growth
Dr Chris Blackwell Chief ExecutiveDownload full statement